WallStreetZenWallStreetZen

NASDAQ: SABS
Sab Biotherapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Sab Biotherapeutics earnings were -$45.6M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest SABS earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$10.3M, up 41.1% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, SABS reported annual earnings of -$42.2M, with 125.1% growth.

SABS earnings history

Current Revenue
$1.5M
Current Earnings
-$45.6M
Current Profit Margin
-3,012.3%

SABS Return on Equity

Current Company
-94.4%
Current Industry
20%
Current Market
35.3%
SABS's Return on Equity (-94.4%)... subscribe to Premium to read more.
High Return on Equity Performance

SABS Return on Assets

Current Company
-67.3%
Current Industry
1.4%
SABS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when SABS announces earnings.

SABS Return on Capital Employed

Current Company
-100.58%
Current Industry
14.3%
SABS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SABS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
SABS-$40.29M-$45.57MN/A-$6.29
FGEN-$97.87M-$121.79MN/A-$1.23
MLEC-$6.18M-$7.31MN/A-$0.19
ANEB-$7.71M-$7.92MN/A-$0.30
AEON-$334.22M-$334.32MN/A-$9.18
View Top Biotech Stocks

Sab Biotherapeutics Earnings Reports & History FAQ

What were Sab Biotherapeutics's earnings last quarter?

On SABS's earnings call on Invalid Date, Sab Biotherapeutics (NASDAQ: SABS) reported Q3 2024 earnings per share (EPS) of -$1.12, up 15.46% year over year. Total SABS earnings for the quarter were -$10.35 million. In the same quarter last year, Sab Biotherapeutics's earnings per share (EPS) was -$0.97.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.

Is Sab Biotherapeutics profitable or losing money?

As of the last Sab Biotherapeutics earnings report, Sab Biotherapeutics is currently losing money. Sab Biotherapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$45.57 million, a 67.46% increase year over year.

What was SABS's earnings growth in the past year?

As of Sab Biotherapeutics's earnings date in Invalid Date, Sab Biotherapeutics's earnings has grown year over year. SABS earnings in the past year totalled -$45.57 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.